Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2009, Article ID 715729, 2 pages
Case Report

Response of Fibroblastic Rheumatism to Infliximab

Departments of Dermatology and Rheumatology, University of São Paulo, 05403-000 São Paulo, SP, Brazil

Received 9 August 2009; Accepted 11 November 2009

Academic Editor: Thomas Ruzicka

Copyright © 2009 Ricardo Romiti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Onset is usually sudden with symmetrical articular involvement of both small and large joints, occurrence of solid skin nodules, and rapid progression. Treatment is generally unrewarding. Here we report a severe and disabling case of FR responding favorably to infliximab therapy. After 32 weeks of continuous treatment, skin lesions dramatically improved and arthropathy partially regressed.